查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829674

2025年全球药物释放型支架市场报告

Drug Eluting Stent Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，药物释放型支架市场呈现强劲成长势头，市场规模从2024年的76.3亿美元增至2025年的82.6亿美元，复合年增长率达8.3%。在过去一段时间内，治疗方案的改进、临床证据的累积、监管部门的核准、医疗经济效益以及对指南和建议的需求推动了市场的成长。

预计未来几年药物释放型支架市场规模将强劲成长，到2029年将达到110.7亿美元，复合年增长率为7.6%。预测期内的成长可归因于人口老化和慢性病负担、适应症扩大、医疗保健报销政策、全球市场扩张以及以患者为中心的医疗等因素。预测期内的主要趋势包括个人化医疗、微创技术、新兴医疗技术和下一代药物製剂。

药物释放型支架 (DES) 是医疗设备。 DES 是一种小型网状管，通常由金属製成，在经经皮冠状动脉介入治疗 (PCI) 或血管成形术中插入狭窄或阻塞的冠状动脉。

药物释放型支架主要分为聚合物基和非聚合物基两种。聚合物基药物释放型支架 (DES) 是一种涂覆薄聚合物层的支架，此层包覆药物，以便输送至动脉壁。这些药物包括Sirolimus、紫杉醇、佐他莫司、Everolimus和比奥莫司，并可采用钴铬合金、铂铬合金、镍钛合金和可生物降解材料等支架。它们被医院和专科诊所等终端用户用于治疗冠状动脉疾病和周边血管疾病。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要医疗设备重新认证，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供药物释放型支架市场统计数据，包括全球药物释放型药物释放型支架行业规模、各地区市场份额、竞争对手的市场份额、详细的药物释放型药物释放型细分市场、市场趋势和商机，以及您在药物释放型支架市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的全方位观点。

未来五年7.6%的预测成长率，较我们先前对该市场的预测略有下降0.6%。下降的主要原因是美国与其他国家之间关税的影响。美国可能会直接感受到这种影响，因为来自比利时和新加坡等主要地区的可生物降解聚合物载体和钴铬合金平台的供应链中断，这可能导致冠状动脉介入治疗的延误和救命心臟设备价格的上涨。此外，这种影响可能会透过互惠关税以及不断升级的贸易紧张局势和限制对全球经济和贸易的负面影响，在更广泛的范围内显现。

预计未来几年，日益严重的水污染水平将推动生态毒性检测市场的成长。水污染是指河流、湖泊、海洋和地下水等水体受到有害污染物的污染，对人类健康、水生生物和环境造成不利影响。污染加剧的因素包括工业废水、含有化学肥料和农药的农业径流、不当的废弃物处理、导致污水污染的都市化以及石油洩漏等。生态毒理学研究评估化学物质和重金属等污染物对水生生物的毒性，并有助于制定污染防治策略，以减轻水污染的有害影响。例如，根据白金汉期货2024年8月发布的数据，预计2022年英格兰河流和海洋的污水排放小时数将达到175万小时，2023年将增加至360万小时。因此，日益严重的水污染正在推动生态毒理学研究的需求。

药物释放型支架市场的公司正专注于开发创新的输送系统，例如双层球囊，以改善患者预后并推动介入性心臟病学的发展。药物释放型支架系统中的双层球囊能使药物均匀且可控地作用于动脉壁，进而提高药物输送和支架置入的精准度。例如，美敦力公司于2022年8月宣布推出其最新一代药物释放型冠状动脉支架系统Onyx Frontier，旨在增强输送系统，并藉鉴上一代Resolute Onyx DES的急性性能和临床数据。 Onyx Frontier DES采用与Resolute Onyx相同的高品质支架平台，尺寸范围广泛，能够使用直径从2.0毫米到5.0毫米不等的支架治疗患者。显着的设计改进，包括创新的双层球囊、减少的横截面积和增加的导管灵活性，与上一代 Resolute Onyx DES 相比，输送能力提高了 16%，同时保持了径向强度。

2023年10月，Cordis收购了MedAlliance，具体金额未揭露。此次收购旨在进一步发扬Cordis在心血管领域的创新传统，并扩大产品系列。 MedAlliance是一家总部位于瑞士的医疗设备製造商和分销商，专注于药物释放型支架。

药物释放型支架市场由提供术前评估、手术介入、术中监测、术后照护和病患教育等服务的营业单位获得的收益所构成。市场价值还包括服务供应商销售或包含在其服务产品中的相关商品的价值。药物释放型支架市场还包括导管导引线、血管成形术装置、血管内影像系统、止血装置和诊断工具等产品的销售。此市场价值为“出厂价”，即商品製造商或生产商销售给其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接销售给最终客户的商品价值。该市场中的商品价值还包括商品製造商销售的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球药物释放型支架：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球药物释放型支架市场：成长率分析
  • 全球药物释放型支架市场表现：规模与成长，2019-2024
  • 全球药物释放型支架市场预测：规模与成长，2024-2029年，2034年
  • 全球药物释放型支架：总目标市场（TAM）

第六章 市场细分

  • 全球药物释放型支架市场（按产品、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 聚合物基
  • 不含聚合物
  • 全球药物释放型支架市场：依药物类型、表现和预测，2019-2024 年、2024-2029 年、2034 年
  • Sirolimus
  • 紫杉醇
  • 佐他莫司
  • Everolimus
  • 百奥利莫斯
  • 其他药物
  • 全球药物释放型支架市场（按支架类型、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 钴铬合金
  • 铂铬
  • 镍钛合金
  • 可生物降解
  • 其他脚手架
  • 全球药物释放型支架市场应用、效能及预测（2019-2024、2024-2029、2034）
  • 冠状动脉疾病
  • 周围血管疾病
  • 全球药物释放型支架市场（按最终用户、性能和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 专科诊所
  • 全球药物释放型支架市场：按聚合物基底、类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 耐用聚合物药物释放型支架
  • 可生物降解聚合物药物释放型支架
  • 全球药物释放型支架市场：按无聚合物、类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 药物涂层裸金属支架
  • 其他无聚合物药物释放型支架

第七章 区域和国家分析

  • 全球药物释放型支架市场：依地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球药物释放型支架市场：依国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 药物释放型支架市场：竞争格局
  • 药物释放型支架市场：公司简介
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Terumo Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • InspireMD Inc.
  • B. Braun Melsungen AG
  • Cook Group Incorporated
  • Lepu Medical Technology（Beijing）Co. Ltd.
  • Biotronik
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Biosensors International Group Ltd.
  • OrbusNeich Medical Company Limited
  • Alvimedica Medical Technologies
  • Hexacath
  • Elixir Medical Corporation
  • Translumina GmbH
  • Cardionovum GmbH
  • QualiMed Innovative Medizinprodukte GmbH

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年药物释放型支架市场：提供新机会的国家
  • 2029年药物释放型支架市场：细分市场带来新机会
  • 2029年药物释放型支架市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r30041u

A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.

The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The drug eluting stent market research report is one of a series of new reports from The Business Research Company that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug eluting stent market size has grown strongly in recent years. It will grow from $7.63 billion in 2024 to $8.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the need for improved treatment options, clinical evidence, regulatory approval, healthcare economics, and guidelines and recommendations.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.07 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to an aging population and chronic disease burden, the expansion of indications, healthcare reimbursement policies, global market expansion, and patient-centered care. Major trends in the forecast period include personalized medicine, minimally invasive techniques, emerging healthcare technologies, and next-generation drug formulations.

The forecast of 7.6% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for biodegradable polymer carriers and cobalt-chromium platforms, sourced from key regions such as Belgium and Singapore, which could lead to delayed coronary interventions and increased prices for life-saving cardiac devices.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising levels of water pollution are expected to drive the growth of the ecotoxicological studies market in the coming years. Water pollution refers to the contamination of water bodies, such as rivers, lakes, oceans, and groundwater, by harmful pollutants, which negatively impact human health, aquatic life, and the environment. The increasing pollution is driven by factors like industrial discharges, agricultural runoff containing fertilizers and pesticides, improper waste disposal, urbanization causing sewage contamination, and oil spills. Ecotoxicological studies assess the toxicity of pollutants, such as chemicals, heavy metals, and other contaminants, on aquatic organisms, helping to develop pollution control strategies to reduce the harmful effects of water pollution. For example, data from Buckingham Futures in August 2024 reported that sewage spills in England's rivers and seas totaled 1.75 million hours in 2022, which increased to 3.6 million hours in 2023. As a result, the growing water pollution is fueling the demand for ecotoxicological studies.

Companies operating in the drug-eluting stent market are directing their efforts toward developing innovative delivery systems, such as the dual-layer balloon, to enhance patient outcomes and advance interventional cardiology. A dual-layer balloon within a drug-eluting stent system improves precision in drug delivery and stent deployment by offering better control and uniform drug application to the arterial wall. For instance, in August 2022, Medtronic Plc introduced Onyx Frontier, the latest generation of drug-eluting coronary stent systems designed to enhance delivery systems, building upon the acute performance and clinical data from the previous Resolute Onyx DES generation. The Onyx Frontier DES utilizes the same high-quality stent platform as Resolute Onyx and features a wide size range to treat patients with diameters ranging from 2.0mm to 5.0mm. Notable design enhancements include a groundbreaking dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility, resulting in a 16% increase in deliverability compared to the previous Resolute Onyx DES generation, while maintaining radial strength.

In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

Major companies operating in the drug eluting stent market are Johnson & Johnson Services Inc., Abbott, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, InspireMD Inc., B. Braun Melsungen AG, Cook Group Incorporated, Lepu Medical Technology (Beijing) Co. Ltd., Biotronik, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Company Limited, Alvimedica Medical Technologies, Hexacath, Elixir Medical Corporation, Translumina GmbH, Cardionovum GmbH, QualiMed Innovative Medizinprodukte GmbH, InSitu Technologies Inc., Acrostak AG, SINOMED Innovation Inc., Svelte Medical Systems Inc.

North America was the largest region in the drug-eluting stent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Eluting Stent Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug eluting stent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug eluting stent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug eluting stent market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Polymer-Based; Polymer-Free
  • 2) By Drug: Sirolimus; Paclitaxel; Zotarolimus; Everolimus; Biolimus; Other Drugs
  • 3) By Scaffold: Cobalt-Chromium; Platinum-Chromium; Nitinol; Biodegradable; Other Scaffolds
  • 4) By Application: Coronary Diseases; Peripheral Vascular Diseases
  • 5) By End-User: Hospitals; Specialty Clinic
  • Subsegments:
  • 1) By Polymer-Based: Durable Polymer Drug-Eluting Stents; Biodegradable Polymer Drug-Eluting Stents
  • 2) By Polymer-Free: Bare-Metal Stents With Drug Coating; Other Polymer-Free Drug-Eluting Stents
  • Companies Mentioned: Johnson & Johnson Services Inc.; Abbott; Medtronic plc; Boston Scientific Corporation; Terumo Corporation; InspireMD Inc.; B. Braun Melsungen AG; Cook Group Incorporated; Lepu Medical Technology (Beijing) Co. Ltd.; Biotronik; Meril Life Sciences Pvt. Ltd.; MicroPort Scientific Corporation; Biosensors International Group Ltd.; OrbusNeich Medical Company Limited; Alvimedica Medical Technologies; Hexacath; Elixir Medical Corporation; Translumina GmbH; Cardionovum GmbH; QualiMed Innovative Medizinprodukte GmbH; InSitu Technologies Inc.; Acrostak AG; SINOMED Innovation Inc.; Svelte Medical Systems Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drug Eluting Stent Market Characteristics

3. Drug Eluting Stent Market Trends And Strategies

4. Drug Eluting Stent Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Drug Eluting Stent Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Drug Eluting Stent PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Drug Eluting Stent Market Growth Rate Analysis
  • 5.4. Global Drug Eluting Stent Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Drug Eluting Stent Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Drug Eluting Stent Total Addressable Market (TAM)

6. Drug Eluting Stent Market Segmentation

  • 6.1. Global Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymer-Based
  • Polymer-Free
  • 6.2. Global Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sirolimus
  • Paclitaxel
  • Zotarolimus
  • Everolimus
  • Biolimus
  • Other Drugs
  • 6.3. Global Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cobalt-Chromium
  • Platinum-Chromium
  • Nitinol
  • Biodegradable
  • Other Scaffolds
  • 6.4. Global Drug Eluting Stent Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Coronary Diseases
  • Peripheral Vascular Diseases
  • 6.5. Global Drug Eluting Stent Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinic
  • 6.6. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Based, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Durable Polymer Drug-Eluting Stents
  • Biodegradable Polymer Drug-Eluting Stents
  • 6.7. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Free, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bare-Metal Stents With Drug Coating
  • Other Polymer-Free Drug-Eluting Stents

7. Drug Eluting Stent Market Regional And Country Analysis

  • 7.1. Global Drug Eluting Stent Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Drug Eluting Stent Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drug Eluting Stent Market

  • 8.1. Asia-Pacific Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drug Eluting Stent Market

  • 9.1. China Drug Eluting Stent Market Overview
  • 9.2. China Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drug Eluting Stent Market

  • 10.1. India Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drug Eluting Stent Market

  • 11.1. Japan Drug Eluting Stent Market Overview
  • 11.2. Japan Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drug Eluting Stent Market

  • 12.1. Australia Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drug Eluting Stent Market

  • 13.1. Indonesia Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drug Eluting Stent Market

  • 14.1. South Korea Drug Eluting Stent Market Overview
  • 14.2. South Korea Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drug Eluting Stent Market

  • 15.1. Western Europe Drug Eluting Stent Market Overview
  • 15.2. Western Europe Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drug Eluting Stent Market

  • 16.1. UK Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drug Eluting Stent Market

  • 17.1. Germany Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drug Eluting Stent Market

  • 18.1. France Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drug Eluting Stent Market

  • 19.1. Italy Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drug Eluting Stent Market

  • 20.1. Spain Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drug Eluting Stent Market

  • 21.1. Eastern Europe Drug Eluting Stent Market Overview
  • 21.2. Eastern Europe Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drug Eluting Stent Market

  • 22.1. Russia Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drug Eluting Stent Market

  • 23.1. North America Drug Eluting Stent Market Overview
  • 23.2. North America Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drug Eluting Stent Market

  • 24.1. USA Drug Eluting Stent Market Overview
  • 24.2. USA Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drug Eluting Stent Market

  • 25.1. Canada Drug Eluting Stent Market Overview
  • 25.2. Canada Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drug Eluting Stent Market

  • 26.1. South America Drug Eluting Stent Market Overview
  • 26.2. South America Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drug Eluting Stent Market

  • 27.1. Brazil Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drug Eluting Stent Market

  • 28.1. Middle East Drug Eluting Stent Market Overview
  • 28.2. Middle East Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drug Eluting Stent Market

  • 29.1. Africa Drug Eluting Stent Market Overview
  • 29.2. Africa Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drug Eluting Stent Market Competitive Landscape And Company Profiles

  • 30.1. Drug Eluting Stent Market Competitive Landscape
  • 30.2. Drug Eluting Stent Market Company Profiles
    • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbott Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Terumo Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Drug Eluting Stent Market Other Major And Innovative Companies

  • 31.1. InspireMD Inc.
  • 31.2. B. Braun Melsungen AG
  • 31.3. Cook Group Incorporated
  • 31.4. Lepu Medical Technology (Beijing) Co. Ltd.
  • 31.5. Biotronik
  • 31.6. Meril Life Sciences Pvt. Ltd.
  • 31.7. MicroPort Scientific Corporation
  • 31.8. Biosensors International Group Ltd.
  • 31.9. OrbusNeich Medical Company Limited
  • 31.10. Alvimedica Medical Technologies
  • 31.11. Hexacath
  • 31.12. Elixir Medical Corporation
  • 31.13. Translumina GmbH
  • 31.14. Cardionovum GmbH
  • 31.15. QualiMed Innovative Medizinprodukte GmbH

32. Global Drug Eluting Stent Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Eluting Stent Market

34. Recent Developments In The Drug Eluting Stent Market

35. Drug Eluting Stent Market High Potential Countries, Segments and Strategies

  • 35.1 Drug Eluting Stent Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Drug Eluting Stent Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Drug Eluting Stent Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer